A.forall Launches Direct Commercialization of Sodium Acetate Injection to Address U.S. Drug Shortage
核心洞察
A.forall (搜索) announced the direct commercialization and launch of Sodium Acetate Injection (搜索) 2mEq/mL through its U.S. subsidiary Milla Pharmaceuticals Inc.
The injectable solution is available in 20mL, 50mL, and 100mL vials and is indicated for preventing or correcting hyponatremia (搜索) in patients with restricted oral intake.
The company has been supplying Sodium Acetate in the U.S. for four years during ongoing shortages and now addresses the shortage directly through its own commercial organization.
A.forall (搜索) has announced the direct commercialization and launch of Sodium Acetate Injection (搜索) 2mEq/mL through its U.S. subsidiary, Milla Pharmaceuticals Inc., marking a significant step in addressing ongoing drug shortages in the American healthcare system. The injectable solution is now available in 20mL, 50mL, and 100mL vials.
Clinical Applications and Indications
Sodium Acetate Injection (搜索), USP serves as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia (搜索) in patients with restricted or no oral intake. The medication also functions as an additive for preparing specific intravenous fluid formulas when standard electrolyte or nutrient solutions cannot meet patient needs.
Addressing Critical Supply Shortages
The launch represents a strategic response to persistent drug shortages affecting U.S. healthcare facilities. Erik Lazarich, A.forall (搜索)'s President of U.S. Operations, emphasized the company's commitment to addressing these challenges directly.
"We continue supplying Sodium Acetate in the U.S. throughout this time of shortage as we have been doing over the last four years, but we are now proudly addressing the shortage directly," Lazarich stated. "Thanks to our own commercial organization, we are now able to provide U.S. patients with the medicines they need most in an even more efficient way."
Strategic Market Positioning
This commercialization milestone reflects A.forall (搜索)'s expanding presence in the U.S. pharmaceutical market. Lazarich noted that the development "represents the company's continued investment in and increasing internal dedication to serving the U.S. marketplace, especially for products which have been or continue to be reported in shortage."
Company Mission and Focus
A.forall (搜索) operates under the mission of "Making Affordable Medicines Available To All," developing value-added generic pharmaceuticals while solving product shortages and filling unmet medical needs. The company aims to enable patients to continue their treatment while reducing healthcare system costs and increasing customer convenience.
Milla Pharmaceuticals Inc., A.forall (搜索)'s U.S. subsidiary, specializes in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market, with particular focus on niche injectable and solution products for hospitals and clinics.